Biol Reprod Lalor Postdoctoral Fellowships -- Application Deadline January 15, 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smith, J. T.
Right arrow Articles by Waddell, B. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, J. T.
Right arrow Articles by Waddell, B. J.
Agricola
Right arrow Articles by Smith, J. T.
Right arrow Articles by Waddell, B. J.
Biology of Reproduction 67, 1204-1210 (2002)
© 2002 Society for the Study of Reproduction, Inc.

Leptin Receptor Expression in the Rat Placenta: Changes in Ob-Ra, Ob-Rb, and Ob-Re with Gestational Age and Suppression by Glucocorticoids1

Jeremy T. Smitha, and Brendan J. Waddell2,a

a School of Anatomy and Human Biology and The Western Australian Institute for Medical Research, The University of Western Australia, Crawley, Perth, Western Australia 6009, Australia


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Leptin, the hormone product of the ob gene, has recently been implicated as an important player in the complex hormonal control of fetal growth. Leptin actions are mediated via the long isoform of its receptor (Ob-Rb), while shorter isoforms may serve as transporters of leptin through physiological barriers (Ob-Ra) or as leptin-binding proteins in plasma (Ob-Re). Placental expression of these receptor isoforms could thus mediate leptin actions within the placenta or regulate transport of maternal, placental, and fetal leptin. In the present study, we show by real-time quantitative reverse-transcription polymerase chain reaction (RT-PCR) that Ob-Ra, Ob-Rb, and Ob-Re mRNAs are dynamically expressed in the functionally distinct basal and labyrinth zones of the rat placenta during the period of maximal fetal growth (i.e., from Day 16 to Day 22 of pregnancy; term = Day 23). Western blot analyses confirmed placental expression of the Ob-Rb protein, and immunolocalization was most prominent in trophoblast and vascular tissues of the labyrinth zone. Ob-Ra and Ob-Re mRNA expression increased markedly (P < 0.01) from Day 16 to Day 22 in the labyrinth but not in the basal zone, whereas Ob-Rb mRNA and protein remained relatively stable. Because glucocorticoids inhibit feto-placental growth, placental leptin receptor (Ob-R) expression was also measured after manipulation of feto-placental glucocorticoid exposure. Maternal treatment with dexamethasone reduced (P < 0.05) placental expression of Ob-Rb mRNA and protein, whereas metyrapone (an inhibitor of glucocorticoid synthesis) stimulated (P < 0.01) placental expression of mRNAs encoding all three Ob-R isoforms. Dexamethasone and carbenoxolone (an inhibitor of the enzyme 11ß-hydroxysteroid dehydrogenase) also markedly reduced (P < 0.01) fetal but not maternal plasma leptin concentrations, consistent with inhibition of transplacental passage of maternal leptin. In conclusion, our data indicate that placental expression of Ob-Ra, Ob-Rb, and Ob-Re is likely to mediate leptin action and transport in the fetus and placenta. The effects of glucocorticoid manipulations on placental expression of these isoforms suggest that glucocorticoid-induced feto-placental growth retardation could be mediated, in part, via inhibition of leptin action or transport in the placenta.

leptin, leptin receptor, placenta, trophoblast


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Fetal growth is regulated by a complex interplay among maternal, placental, and fetal endocrine signals [1, 2]. Recently, the 16-kDa peptide leptin, the product of the ob gene produced primarily by adipocytes, has been proposed as an additional key player in this regulation [35]. Accordingly, concentrations of leptin in human cord blood correlate positively with both placental size and birthweight [3, 6, 7], and fetal weight is correlated with placental leptin levels following experimental manipulations in heterozygote leptin receptor-deficient mice [5]. Potentially, positive effects of leptin on fetal growth could be mediated directly within the fetus or indirectly via effects on maternal metabolism and/or placental function. Recently, we demonstrated that maternal plasma leptin levels rise progressively until late pregnancy in the rat in association with increased plasma leptin-binding activity [8]. Studies in the pregnant mouse suggest that this increase in binding activity is due to placental secretion of a soluble form of the leptin receptor (Ob-Re) [9]. This soluble isoform is one of six splice variants of the leptin receptor (Ob-R) that have been identified [10, 11], and these fall into three categories: a long form (Ob-Rb) capable of full signal transduction; a number of C-terminally truncated forms (Ob-Ra, Ob-Rc, Ob-Rd, Ob-Rf), among which Ob-Ra has been the most studied and may act as a transporter of leptin through physiological barriers; and Ob-Re, which contains only the extracellular domain and acts as a leptin-binding protein (for review, see [11]). Thus, placental expression of all three Ob-R isoforms could influence leptin actions on fetal growth by mediating leptin transport (via Ob-Ra), direct leptin actions within the placenta (via Ob-Rb), and leptin bioavailability (via Ob-Re). Although placental expression of a number of Ob-R isoforms has been reported in humans [12, 13] and rodents [9, 14, 15], their spatial variation within the rat placenta (basal and labyrinth zones) and possible changes with gestational age and fetal growth retardation have not been investigated. In the present study, therefore, Ob-Ra, Ob-Rb, and Ob-Re mRNA expression and Ob-Rb protein expression were examined in the rat placenta during the final third of rat pregnancy, the period of maximal fetal and placental growth. Separate analyses were made in the two morphologically and functionally distinct regions of the placenta, the basal and labyrinth zones, because only the latter is involved in maternal-fetal transport. Fetal and maternal plasma leptin and placental Ob-R isoform expression were also measured in models of altered feto-placental glucocorticoid exposure. These models were examined because glucocorticoids are known to potently reduce feto-placental growth [16, 17] and inhibit leptin action in target tissues [18, 19]. On the other hand, glucocorticoids stimulate leptin production by adipocytes [19, 20], an effect recently observed during late pregnancy in the rat [21].


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Animals

Nulliparous albino Wistar rats aged between 9 and 12 wk were obtained from the Animal Resources Centre (Murdoch, Australia) and maintained under controlled conditions as previously described [16]. Rats were mated overnight, and the day on which spermatozoa were present in vaginal smear was designated gestational Day 1. Rats in this colony normally deliver on Day 23. All procedures involving animals were conducted only after approval by the Animal Ethics Committee of The University of Western Australia.

Experimental Glucocorticoid Manipulations

Increased glucocorticoid exposure was achieved both systemically by maternal dexamethasone treatment and locally within the placenta by treatment with carbenoxolone, an inhibitor of 11ß-hydroxysteroid dehydrogenase (11ß-HSD), from Day 13 to Day 22 of pregnancy. Dexamethasone acetate was administered in drinking water (1 µg/ml) and carbenoxolone was administered twice daily (10 mg in 4% ethanol-saline, 0.1 ml s.c. injection at 0700 and 1730 h) over the same period. We have previously shown that these treatments reduce birthweight by 27% and 8%, respectively [17]. To reduce glucocorticoid exposure, mothers were treated with the 11ß-hydroxylase inhibitor, metyrapone, administered in physiological saline (in place of drinking water) at a concentration of 500 µg/ml; we have previously shown that this treatment enhances fetal and placental growth [16, 17].

Tissue Collection

On the day of tissue collection (Day 16 or Day 22), rats were anesthetized with halothane/nitrous oxide and uterine horns were exposed. Whole placentas were removed and immediately immersed in ice-cold MB Histochoice fixative (Amresco, Solon, OH) for 4 h, then processed for routine paraffin histology [22]. Additional placentas were dissected into the basal and labyrinth zones, snap frozen on liquid nitrogen, and stored at -80°C for subsequent Western blot and reverse-transcription polymerase chain reaction (RT-PCR) analyses.

Radioimmunoassay of Plasma Leptin

Blood samples were obtained at Day 22 of gestation from fetuses by decapitation (blood from four fetuses from each mother was pooled to provide sufficient volume), and maternal blood was collected from the dorsal aorta. The samples were collected into heparinized tubes, centrifuged at 11 000 rpm for 5 min, and plasma stored at -20°C until assayed. Plasma leptin concentrations were measured using a radioimmunoassay kit supplied by Linco Research (St. Charles, MO). The intra- and interassay coefficients of variation were 4.0% and 4.5%, respectively.

Immunocytochemical Analyses

Ob-R was immunolocalized in placental sections (5 µm) mounted on poly-L-lysine-coated slides (Sigma, St. Louis, MO) as previously described for localization of 11ß-HSD enzymes [22]. Briefly, endogenous peroxidase activity was blocked by incubation in 1% hydrogen peroxide in methanol for 10 min, and nonspecific binding was blocked by incubation with 1.5% BSA (Sigma) in PBS containing 0.1% Triton X. Sections were then incubated overnight at 4°C with primary antibody (diluted 1:50; K-20; Santa Cruz Biotechnology, Santa Cruz, CA) and then with biotinylated horse anti-goat secondary antibody (diluted 1:200; Vector Laboratories, Burlingame, CA) followed by Vectastain Elite ABC solution (Vector Laboratories). Positive signal was visualized using diaminobenzidene (DAB; Sigma), and sections were counterstained with Gill hematoxylin; no signal was evident after preincubation with blocking peptide (Santa Cruz Biotechnology) or in the absence of primary antibody. Because the primary antibody was generated against the common region of the Ob-R, it theoretically cross-reacts with all three major isoforms; by Western analysis, however, only the 120-kDa Ob-Rb isoform [23] was detected (see Results).

Western Blot Analysis

Western blot analysis was performed essentially as described by Shioda et al. [24]. Briefly, portions of basal and labyrinth tissue were homogenized (2 vol 10 mM Tris buffer containing 1.5 mM EDTA, 1 mM DTT, 1 mM PMSF, and 100 µg/ml trypsin inhibitor) and centrifuged at 105 000 x g for 30 min. Supernatant protein (100 µg) was resolved by SDS-PAGE (7% separating) and transferred to nitrocellulose membrane (Hybond C-Super, Amersham Pharmacia Biotech, Sydney, Australia). Membranes were incubated for 1 h in blocking solution containing 5% nonfat milk, then overnight at 4°C with Ob-R antibody (diluted 1:400, K-20; Santa Cruz Biotechnology). To identify immunoreactive bands, membranes were incubated with HRP-conjugated donkey anti-goat secondary antibody (diluted 1:5000; Chemicon International, Temecula, CA) and signals visualized using a chemiluminescence detection kit (SuperSignal Substrate, Pierce Chemical, Rockford, IL). Resultant autoradiographs were quantified by densitometry using Scion Image analysis software (Release beta 3b) as previously described [25].

Real-Time Quantitative RT-PCR Analysis

Total RNA from placental zones was isolated, reverse transcribed, and the resultant cDNA purified and quantified as previously described [8]. The cDNA primers to specific rat Ob-R isoforms [26] were positioned to span intron-exon junctions to distinguish cDNA from genomic DNA and were as follows: Ob-Ra, sense 5'-ATGAAGTGGCTTAGAATCCCTTCG-3', antisense 5'-TACTTCAAAGAGTGTCCGCTC-3'; Ob-Rb, sense 5'-ATGAAGTGGCTTAGAATCCCTTCG-3', antisense 5'-ATATCACTGATTCTGCATGCT-3'; Ob-Re, sense 5'-TTCCTGTGGGCAGAATCAGCACACACTGTT-3', antisense 5'-AAGCACAGTACACATACC-3' (GeneWorks, Adelaide, Australia). External standards were generated from regular PCR products (347, 375, and 305 base pairs, respectively, for Ob-Ra, Ob-Rb, and Ob-Re) and serial dilutions made in RNase-free water (1–107-fold dilutions).

Quantitative PCR and melting-curve analyses were performed in 10 µl reaction volumes in capillary tubes using the LightCycler system (Roche Diagnostics, Indianapolis, IN) as previously described for Ob-Rb [8]. Primers (as above) and MgCl2 concentrations were optimized as follows: Ob-Ra, primers 0.3 µM, MgCl2 3 mM; Ob-Rb, primers 0.3 µM, MgCl2 3 mM; Ob-Re, primers 0.4 µM, MgCl2 2 mM. The PCR cycling conditions included an initial denaturation at 95°C for 10 min followed by 55 cycles at 95°C for 15 sec; 54°C for 5 sec (Ob-Re 50°C), and 72°C for 16 sec. Melting-curve analysis showed a single PCR product for each Ob-R isoform, and this was confirmed by gel electrophoresis (data not shown). Fluorescence values were analyzed and a standard curve constructed using the LightCycler software. The intra- and interassay coefficients of variation, respectively, were as follows: Ob-Ra, 0.5% and 0.3%; Ob-Rb, 0.5% and 2.0%; Ob-Re, 0.2% and 0.3%.

Statistical Analysis

All data are expressed as the mean ± SEM, where a minimum of three animals was used for each experimental variable and each litter represented an n of one. Variation in Ob-R protein and mRNA expression related to placental zone, stage of pregnancy, or treatment was assessed by one- or two-way ANOVAs as appropriate. The effects of glucocorticoid manipulations on maternal and fetal plasma leptin were assessed by one-way ANOVAs. Where the F-test for the ANOVA reached statistical significance (P < 0.05), differences among specific means were assessed by least significant difference (LSD) tests [27].


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Placental Expression of Ob-R Isoforms

Expression of mRNAs encoding Ob-Ra, Ob-Rb, and Ob-Re were detected in both the basal and labyrinth zones of the rat placenta at Days 16 and 22 of pregnancy (Fig. 1). Expression of Ob-Ra and Ob-Re mRNAs both varied with gestational age (P < 0.05) and placental zone (P < 0.02), and in each case, there was significant interaction between these sources of variation (P < 0.05, two-way ANOVA). Specifically, the major effects were that both Ob-Ra and Ob-Re mRNA expression increased (P < 0.01) in the labyrinth zone from Day 16 to Day 22 (by 4.8- and 1.9-fold, respectively), whereas basal zone expression of both isoforms remained relatively stable. Expression of Ob-Rb appeared slightly higher in labyrinth zone at both stages of pregnancy, but this just failed to reach statistical significance (P = 0.07, two-way ANOVA). Regardless of stage of pregnancy or placental zone, expression of Ob-Re clearly exceeded that of Ob-Ra and Ob-Rb (by 3.7- to 10.7-fold).



View larger version (15K):
[in this window]
[in a new window]
 
FIG. 1. Quantification of placental Ob-Ra, Ob-Rb, and Ob-Re mRNA in the basal (Bas) and labyrinth (Lab) zones of rat placenta at Day 16 (d16) and Day 22 (d22) of pregnancy by real-time RT-PCR. Values are expressed as pg RNA/µg total cDNA and are the mean ± SEM (n = 4 per group). Ob-Ra and Ob-Re varied with gestational age (P < 0.05) and placental zone (P < 0.02), both with significant interaction (P < 0.05, two-way ANOVA). For each graph, values without common notations (a and b) differ significantly (P < 0.01, one-way ANOVA, LSD test)

Western analysis of Ob-R showed a clear immunoreactive signal at the expected size of Ob-Rb (120 kDa [23]) in both basal and labyrinth zones at Days 16 and 22 (Fig. 2). Generally, expression of Ob-Rb protein was consistent with Ob-Rb mRNA expression, although Ob-Rb protein did fall significantly (36%, P < 0.05) in basal zone from Day 16 to Day 22. A second immunoreactive band was observed at 50 kDa in all samples, but this did not vary with either gestational age or placental zone (data not shown).



View larger version (49K):
[in this window]
[in a new window]
 
FIG. 2. Western blot analysis of leptin receptor (Ob-Rb) protein expression in the basal (Bas) and labyrinth (Lab) zones of rat placenta at Day 16 (d16) and Day 22 (d22) of pregnancy. Values are expressed in arbitrary density units and are the mean ± SEM (n = 6–9 per group). Ob-Rb protein varied with stage of pregnancy (P < 0.02) but not with placental zone (P = 0.62, two-way ANOVA). Values without common notations (a and b) differ significantly (P < 0.05, LSD test)

Immunocytochemical localization of the Ob-R confirmed its presence in both the basal and labyrinth zones at Days 16 and 22 (Fig. 3). Specifically, immunostaining was apparent in trophoblast tissue at both stages of pregnancy and within the adventitial layer of fetal blood vessels in the placental labyrinth zone, particularly at Day 22 (Fig. 3b).



View larger version (116K):
[in this window]
[in a new window]
 
FIG. 3. Immunolocalization of Ob-R in basal (Bas) and labyrinth (Lab) zones of the rat placenta at Day 22 of pregnancy. Note immunolocalization in trophoblast cells (a) and in placental blood vessels (b). Bars = 50 µm

Effects of Glucocorticoid Manipulations on Placental Ob-R Expression

Fetal weight in untreated animals (5.34 ± 0.17 g) was significantly greater than that in animals treated with dexamethasone (3.59 ± 0.17 g; P < 0.001) or carbenoxolone (4.62 ± 0.11 g; P < 0.05). In contrast, fetal weight appeared to be elevated after treatment with metyrapone (5.77 ± 0.20 g), although this just failed to reach statistical significance (difference = 0.43 g; LSD0.05 = 0.49 g). Placental expression of Ob-Ra, Ob-Rb, and Ob-Re mRNAs each varied with glucocorticoid manipulation and with placental zone (each P < 0.01, separate two-way ANOVAs). Specifically, Ob-Rb expression in the labyrinth zone declined by 32% (P < 0.05) after dexamethasone treatment but increased by 39% following suppression of endogenous glucocorticoid synthesis by metyrapone (P < 0.05; Fig. 4). Similar effects were observed for Ob-Rb expression in the basal zone, but differences reached statistical significance (P < 0.05) only between the metyrapone and the dexamethasone or carbenoxolone groups. Metyrapone treatment also markedly increased (P < 0.01) placental mRNA expression of Ob-Ra (basal, 2.2-fold increase; labyrinth, 1.9-fold) and Ob-Re (basal, 3.5-fold; labyrinth, 2.3-fold), but dexamethasone and carbenoxolone were without effect on expression of these isoforms.



View larger version (24K):
[in this window]
[in a new window]
 
FIG. 4. Quantification of placental Ob-Ra, Ob-Rb, and Ob-Re mRNA expression by real-time RT-PCR in the basal (Bas) and labyrinth (Lab) zones of placentas at Day 22 of rat pregnancy after no treatment (Con) and after maternal treatment with dexamethasone (Dex), carbenoxolone (CBX), or metyrapone (Met) from Day 13 to Day 22. Values are expressed as pg RNA/µg total cDNA and are the mean ± SEM (n = 3–4 per group). For each placental zone, values without common notations (a, b, and c) differ significantly (Ob-Rb, P < 0.05; Ob-Ra and Ob-Re, P < 0.01, one-way ANOVA, LSD tests)

Placental expression of the 120-kDa Ob-Rb protein also varied significantly with treatment (P < 0.01), and these effects were generally consistent with those observed for Ob-Rb mRNA (compare Figs. 4 and 5). Specifically, dexamethasone reduced Ob-Rb protein in the basal zone by 46% (P < 0.02, Fig. 5), and carbenoxolone reduced Ob-Rb expression relative to the metyrapone group (37%, P < 0.05) but not the control group (26%, not significant). A similar trend was observed for Ob-Rb protein expression in the labyrinth zone among the four groups, but this did not reach statistical significance. The 50-kDa signal was again seen in all samples, but this did not vary significantly with either treatment or placental zone (data not shown).



View larger version (54K):
[in this window]
[in a new window]
 
FIG. 5. Western blot analysis of placental Ob-Rb protein in the basal (Bas) and labyrinth (Lab) zones of rat placenta at Day 22 of pregnancy after no treatment (Con) and after maternal treatment with dexamethasone (Dex), carbenoxolone (CBX), or metyrapone (Met) from Day 13 to Day 22. Values are expressed in arbitrary density units and are the mean ± SEM (n = 4–5 per group). Ob-Rb protein varied with treatment (P < 0.01) but not with placental zone (P = 0.70, two-way ANOVA). For basal zone, values without common notations (a, b, and c) differ significantly (P < 0.05, LSD test)

Effects of Glucocorticoid Manipulations on Maternal> and Fetal Plasma Leptin

Treatment of pregnant mothers with dexamethasone resulted in a 2.7-fold increase (P < 0.01) in maternal plasma leptin but an 82% decrease (P < 0.001) in fetal plasma leptin (Fig. 6). Carbenoxolone also reduced fetal plasma leptin (52%, P < 0.01) but had no effect on maternal leptin, whereas metyrapone had no effect on either maternal or fetal plasma leptin concentrations.



View larger version (16K):
[in this window]
[in a new window]
 
FIG. 6. Plasma leptin concentrations in the maternal and fetal circulation at Day 22 of pregnancy after no treatment (Con) and after maternal treatment with dexamethasone (Dex), carbenoxolone (CBX), or metyrapone (Met) from Day 13 to Day 22. Values are the mean ± SEM (n = 3–6 per group). There was significant variation within each compartment (maternal or fetal; P < 0.01, one-way ANOVA), and values without common notations (a, b, and c) differ significantly (P < 0.05, LSD tests)


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Leptin, the 16-kDa peptide product of the ob gene produced primarily by adipocytes, has recently been proposed as a key player in the regulation of fetal and placental growth [35]. The present work supports such a role for leptin in the placenta because mRNA and protein for the signal transduction isoform, Ob-Rb, were readily detected in both the basal and labyrinth zones of the rat placenta during the period of maximal fetal growth. Moreover, placental Ob-Rb expression was markedly reduced in association with glucocorticoid-induced feto-placental growth retardation. Our data further show that the rat placenta expresses mRNAs encoding the other major Ob-R isoforms, Ob-Ra and Ob-Re, in dynamic and zone-specific patterns, both with important functional implications. Thus, the high expression of Ob-Ra in the placental labyrinth zone near term supports the contention that maternal leptin traverses the placenta to the fetal circulation while placental secretion of the Ob-Re isoform is likely to contribute to the pregnancy-induced rise in maternal plasma leptin [8]. Finally, the suppressive effects of increased systemic glucocorticoids on fetal plasma leptin and placental expression of Ob-Rb mRNA and protein suggest that glucocorticoid-induced feto-placental growth retardation is mediated, in part, by reduced leptin action and/or transport in the placenta.

Placental expression of Ob-Rb, the only isoform with full signal transduction capability [11], was readily detected by RT-PCR and Western analysis, particularly in the labyrinth zone, which also displayed the highest Ob-R immunolocalization. This placental region is the site of maternal-fetal exchange and undergoes considerable growth (more than threefold increase in weight [28]) over the period of gestation studied. Quantitative RT-PCR analysis showed that Ob-Ra and Ob-Re were also expressed in the two placental zones, and at Day 22, expression of both isoforms clearly exceeded that of Ob-Rb in the labyrinth zone. Interestingly, Western analysis showed a strong immunoreactive signal at 50 kDa, as previously reported for other tissues [29, 30]. This molecular weight species appears too small to be either Ob-Ra or Ob-Re, and Hill et al. [29] have suggested that it may be a breakdown product of the Ob-Re isoform. Regardless of its precise identity, there was no evidence of any change in expression of this 50-kDa species with gestational age, placental zone, or glucocorticoid manipulation.

Immunolocalization of Ob-R to trophoblast cells suggests that leptin is likely to exert direct effects on placental function. Given the highly proliferative state of the placenta over the last week of pregnancy and the proposed role of leptin as a fetal growth factor [3, 57], leptin may exert a mitogenic effect on trophoblast, similar to its role in the skin [31]. Indeed, our observation that dexamethasone suppresses both placental growth [16] and Ob-Rb expression further supports this contention. Moreover, immunolocalization of Ob-R to placental blood vessels is consistent with the proposed role of leptin as an angiogenic factor [32], which may be particularly important during the rapid and marked growth of the labyrinth zone during late pregnancy.

The Ob-Ra isoform is thought to promote the transport of leptin across physiological barriers, a process that occurs preferentially from the apical to basal surface of cells in vitro [33]. Such a role for Ob-Ra is supported by its relatively high expression in choroid plexus and microvessels of the brain [34]. Because the labyrinth zone of the rat placenta is the site of feto-maternal exchange, its relatively high expression of Ob-Ra, especially at Day 22 of pregnancy, is consistent with a role for this isoform in the transplacental passage of maternal leptin to the fetus. Consistent with this proposal, we have recently observed an increase in the passage of 125I-leptin from maternal to fetal blood between Days 16 and 22 of rat pregnancy (unpublished results). This transport of maternal leptin across the placenta is likely to be of particular importance in rodents because, unlike the human placenta [35], that of rodents appears to synthesize little if any de novo leptin [36, 37].

Placental expression of mRNA encoding the soluble isoform Ob-Re was clearly the highest among the three isoforms, particularly in the labyrinth zone, and this expression is consistent with our recent observation that plasma leptin-binding activity increases progressively until late pregnancy [8]. Thus, the rat appears similar to the mouse in that placental Ob-Re is secreted into the maternal circulation and thereby increases plasma leptin-binding activity [9]. Further studies are required to establish the role, if any, of placental Ob-Re within the fetal circulation.

The inhibition of placental Ob-Rb expression (both mRNA and protein) following treatment with dexamethasone is consistent with previous reports suggesting that glucocorticoids act as counterregulatory hormones to leptin action [18, 19]. The fall in Ob-Rb expression would be expected to limit any growth-promoting effects of leptin in the placenta and thus may contribute to glucocorticoid suppression of placental growth. The inhibitory effect of glucocorticoids on Ob-Rb expression appears to operate across the full physiological range of concentrations because inhibition of endogenous glucocorticoid synthesis by metyrapone enhanced expression of mRNA encoding Ob-Rb as well as those for Ob-Ra and Ob-Re. This further suggests that placental expression of all three Ob-R isoforms is tonically suppressed by basal levels of endogenous glucocorticoids, highlighting the need for local glucocorticoid levels to be tightly regulated within the placenta. We have previously demonstrated that this regulation is mediated by zone-specific expression of the 11ß-HSD enzymes in the placenta [28].

Dexamethasone treatment also increased plasma leptin concentrations in the maternal compartment but had the opposite effect on plasma leptin in the fetus, similar to recent observations by Sugden et al. [21]. The increase in maternal leptin following dexamethasone treatment likely reflects stimulation of maternal adipocyte leptin production as previously reported [19, 20], but the reasons for reduced plasma leptin levels in the fetus are unclear. One explanation is that maternal dexamethasone treatment compromised transplacental passage of maternal leptin to the fetus. Consistent with this explanation, we have recently observed that maternal dexamethasone treatment reduces the transplacental passage of 125I-leptin from the mother to the fetus (unpublished results). Interestingly, despite this reduction in placental leptin transport, the present work shows that expression of Ob-Ra, the isoform normally associated with transport of leptin, is unaffected by dexamethasone. Recent work in the rodent brain indicates that Ob-Rc may also be an important player in leptin transport [38], and so it would be of interest to assess whether this isoform is also expressed in the placenta and if its expression is reduced by glucocorticoids. In addition, glucocorticoid-induced changes in nonspecific mediators of maternal-fetal leptin transport, such as placental blood flow and placental surface area, could also account for the apparent reduction in placental leptin transport.

In conclusion, this study shows that the three major isoforms of the leptin receptor, Ob-Ra, Ob-Rb, and Ob-Re, are all expressed in the rat placenta, each with distinct spatial and temporal patterns. Manipulation of placental glucocorticoid exposure markedly altered expression of all Ob-R isoforms, consistent with a positive role for leptin on fetal and placental growth.


    ACKNOWLEDGMENTS
 
The authors wish to thank Ms. Sue Hisheh for her expert technical assistance.


    FOOTNOTES
 
1 This work was supported by the National Health and Medical Research Council of Australia (project grant 139104). J.T.S. was supported by an Australian Postgraduate Research Award. Back

2 Correspondence: Brendan Waddell, School of Anatomy and Human Biology, The University of Western Australia, 35 Stirling Highway, Crawley, Western Australia 6009, Australia. FAX: 61 8 9380 1051; bwaddell{at}anhb.uwa.edu.au Back

Received: 14 March 2002.

First decision: 10 April 2002.

Accepted: 15 May 2002.


    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Fowden AL. Endocrine regulation of fetal growth. Reprod Fertil Dev 1995 7:351-363[CrossRef][Medline]
  2. Bauer MK, Harding JE, Bassett NS, Breier BH, Oliver MH, Gallaher BH, Evans PC, Woodall SM, Gluckman PD. Fetal growth and placental function. Mol Cell Endocrinol 1998 140:115-120[CrossRef][Medline]
  3. Hassink SG, de Lancey E, Sheslow DV, Smith-Kirwin SM, O'Connor DM, Considine RV, Opentanova I, Dostal K, Spear ML, Leef K, Ash M, Spitzer AR, Funanage VL. Placental leptin: an important new growth factor in intrauterine and neonatal development?. Pediatrics 1997 100:E1
  4. Ashworth CJ, Hoggard N, Thomas L, Mercer JG, Wallace JM, Lea RG. Placental leptin. Rev Reprod 2000 5:18-24[Abstract]
  5. Yamashita H, Shao J, Ishizuka T, Klepcyk PJ, Muhlenkamp P, Qiao L, Hoggard N, Friedman JE. Leptin administration prevents spontaneous gestational diabetes in heterozygous Lepr(db/+) mice: effects on placental leptin and fetal growth. Endocrinology 2001 142:2888-2897[Abstract/Free Full Text]
  6. Schubring C, Kiess W, Englaro P, Rascher W, Dotsch J, Hanitsch S, Attanasio A, Blum WF. Levels of leptin in maternal serum, amniotic fluid, and arterial and venous cord blood: relation to neonatal and placental weight. J Clin Endocrinol Metab 1997 82:1480-1483[Abstract/Free Full Text]
  7. Gomez L, Carrascosa A, Yeste D, Potau N, Rique S, Ruiz-Cuevas P, Almar J. Leptin values in placental cord blood of human newborns with normal intrauterine growth after 30–42 weeks of gestation. Horm Res 1999 51:10-14[CrossRef][Medline]
  8. Seeber RM, Smith JT, Waddell BJ. Plasma leptin binding activity and hypothalamic leptin receptor expression during pregnancy and lactation in the rat. Biol Reprod 2002 66:1762-1767[Abstract/Free Full Text]
  9. Gavrilova O, Barr V, Marcus-Samuels B, Reitman M. Hyperleptinemia of pregnancy associated with the appearance of a circulating form of the leptin receptor. J Biol Chem 1997 272:30546-30551[Abstract/Free Full Text]
  10. Wang MY, Zhou YT, Newgard CB, Unger RH. A novel leptin receptor isoform in rat. FEBS Lett 1996 392:87-90[CrossRef][Medline]
  11. Tartaglia LA. The leptin receptor. J Biol Chem 1997 272:6093-6096[Free Full Text]
  12. Henson MC, Swan KF, O'Neil JS. Expression of placental leptin and leptin receptor transcripts in early pregnancy and at term. Obstet Gynecol 1998 92:1020-1028[Abstract]
  13. Bodner J, Ebenbichler CF, Wolf HJ, Muller-Holzner E, Stanzl U, Gander R, Huter O, Patsch JR. Leptin receptor in human term placenta: in situ hybridization and immunohistochemical localization. Placenta 1999 20:677-682[CrossRef][Medline]
  14. Kawai M, Murakami T, Otani S, Shima K, Yamaguchi M, Kishi K. Colocalization of leptin receptor (OB-R) mRNA and placental lactogen-II in rat trophoblast cells: gestational profile of OB-R mRNA expression in placentae. Biochem Biophys Res Commun 1999 257:425-430[CrossRef][Medline]
  15. Hoggard N, Hunter L, Lea RG, Trayhurn P, Mercer JG. Ontogeny of the expression of leptin and its receptor in the murine fetus and placenta. Br J Nutr 2000 83:317-326[Medline]
  16. Burton PJ, Waddell BJ. 11ß-Hydroxysteroid dehydrogenase in the rat placenta: developmental changes and the effects of altered glucocorticoid exposure. J Endocrinol 1994 143:505-513[Abstract/Free Full Text]
  17. Smith JT, Waddell BJ. Increased fetal glucocorticoid exposure delays puberty onset in postnatal life. Endocrinology 2000 141:2422-2428[Abstract/Free Full Text]
  18. Ur E, Grossman A, Despres JP. Obesity results as a consequence of glucocorticoid induced leptin resistance. Horm Metab Res 1996 28:744-777[Medline]
  19. Zakrzewska KE, Cusin L, Sainsbury A, Rohner-Jeanrenaud F, Jeanrenaud B. Glucocorticoids as counterregulatory hormones of leptin: toward an understanding of leptin resistance. Diabetes 1997 46:717-719[Abstract]
  20. Slieker LJ, Sloop KW, Surface PL, Kriauciunas A, LaQuier F, Manetta J, Bue-Valleskey J, Stephens TW. Regulation and expression of ob mRNA and protein by glucocorticoids and cAMP. J Biol Chem 1996 271:5301-5304[Abstract/Free Full Text]
  21. Sugden MC, Langdown ML, Munns MJ, Holness MJ. Maternal glucocorticoid treatment modulates placental leptin and leptin receptor expression and materno-fetal leptin physiology during late pregnancy, and elicits hypertension associated with hyperleptinaemia in the early-growth-retarded adult offspring. Eur J Endocrinol 2001 145:529-539[Abstract]
  22. Burton PJ, Dharmarajan AM, Hisheh S, Waddell BJ. Induction of myometrial 11ß-hydroxysteroid dehydrogenase type 1 messenger ribonucleic acid and protein expression late in rat pregnancy. Endocrinology 1996 137:5700-5706[Abstract]
  23. Wang MY, Koyama K, Shimabukuro M, Newgard CB, Unger RH. OB-Rb gene transfer to leptin-resistant islets reverses diabetogenic phenotype. Proc Natl Acad Sci U S A 1998 95:714-718[Abstract/Free Full Text]
  24. Shioda S, Funahashi H, Nakajo S, Yada T, Maruta O, Nakai Y. Immunohistochemical localization of leptin receptor in the rat brain. Neurosci Lett 1998 243:41-44[CrossRef][Medline]
  25. Burton PJ, Krozowski ZS, Waddell BJ. Immunolocalization of 11ß-hydroxysteroid dehydrogenase types 1 and 2 in rat uterus: variation across the estrous cycle and regulation by estrogen and progesterone. Endocrinology 1998 139:376-382[Abstract/Free Full Text]
  26. Takaya K, Ogawa Y, Isse N, Okazaki T, Satoh N, Masuzaki H, Mori K, Tamura N, Hosoda K, Nakao K. Molecular cloning of rat leptin receptor isoform complementary DNAs—identification of a missense mutation in Zucker fatty (fa/fa) rats. Biochem Biophys Res Commun 1996 225:75-83[CrossRef][Medline]
  27. Snedecor GW, Cochran WG. Statistical Methods, 8th ed. Ames, IA: Iowa State University Press; 1989
  28. Waddell BJ, Benediktsson R, Brown RW, Seckl JR. Tissue-specific messenger ribonucleic acid expression of 11ß-hydroxysteroid dehydrogenase types 1 and 2 and the glucocorticoid receptor within rat placenta suggests exquisite local control of glucocorticoid action. Endocrinology 1998 139:1517-1523[Abstract/Free Full Text]
  29. Hill RA, Margetic S, Pegg GG, Gazzola C. Leptin: its pharmacokinetics and tissue distribution. Int J Obes Relat Metab Disord 1998 22:765-770[CrossRef][Medline]
  30. El-Hefnawy T, Ioffe S, Dym M. Expression of the leptin receptor during germ cell development in the mouse testis. Endocrinology 2000 141:2624-2630[Abstract/Free Full Text]
  31. Frank S, Stallmeyer B, Kampfer H, Kolb N, Pfeilschifter J. Leptin enhances wound re-epithelialization and constitutes a direct function of leptin in skin repair. J Clin Invest 2000 106:501-509[Medline]
  32. Bouloumie A, Drexler HCA, Lafontan M, Busse R. Leptin, the product of the ob gene, promotes angiogenesis. Circ Res 1998 83:1059-1066[Abstract/Free Full Text]
  33. Hileman SM, Tornoe J, Flier JS, Bjorbaek C. Transcellular transport of leptin by the short leptin receptor isoform ObRa in Madin-Darby canine kidney cells. Endocrinology 2000 141:1955-1961[Abstract/Free Full Text]
  34. Bjorbaek C, Elmquist JK, Michl P, Ahima RS, van Bueren A, McCall AL, Flier JS. Expression of leptin receptor isoforms in rat brain microvessels. Endocrinology 1998 139:3485-3491[Abstract/Free Full Text]
  35. Masuzaki H, Ogawa Y, Sagawa N, Hosoda K, Matsumoto T, Mise H, Nishimura H, Yoshimasa Y, Tanaka I, Mori T, Nakao K. Nonadipose tissue production of leptin: leptin as a novel placenta-derived hormone in humans. Nat Med 1997 3:1029-1033[CrossRef][Medline]
  36. Kawai M, Yamaguchi M, Murakami T, Shima K, Murata Y, Kishi K. The placenta is not the main source of leptin production in pregnant rat: gestational profile of leptin in plasma and adipose tissues. Biochem Biophys Res Commun 1997 240:798-802[CrossRef][Medline]
  37. Amico JA, Thomas A, Crowley RS, Burmeister LA. Concentrations of leptin in the serum of pregnant, lactating, and cycling rats and of leptin messenger ribonucleic acid in rat placental tissue. Life Sci 1998 63:1387-1395[CrossRef][Medline]
  38. Hileman SM, Pierroz DD, Masuzaki H, Bjorbaek C, El-Haschimi K, Banks WA, Flier JS. Characterization of short isoforms of the leptin receptor in rat cerebral microvessels and of brain uptake of leptin in mouse models of obesity. Endocrinology 2002 143:775-783[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
ReproductionHome page
I C McMillen, L J Edwards, J Duffield, and B S Muhlhausler
Regulation of leptin synthesis and secretion before birth: implications for the early programming of adult obesity.
Reproduction, March 1, 2006; 131(3): 415 - 427.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
M. C. Henson and V. D. Castracane
Leptin in Pregnancy: An Update
Biol Reprod, February 1, 2006; 74(2): 218 - 229.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
N. Gallardo, C. Arribas, M. Villar, M. Ros, J. M. Carrascosa, C. Martinez, and A. Andres
ObRa and ObRe Are Differentially Expressed in Adipose Tissue in Aged Food-Restricted Rats: Effects on Circulating Soluble Leptin Receptor Levels
Endocrinology, November 1, 2005; 146(11): 4934 - 4942.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
S. R. Ladyman and D. R. Grattan
Suppression of Leptin Receptor Messenger Ribonucleic Acid and Leptin Responsiveness in the Ventromedial Nucleus of the Hypothalamus during Pregnancy in the Rat
Endocrinology, September 1, 2005; 146(9): 3868 - 3874.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
I. C. McMillen, C. L. Adam, and B. S. Muhlhausler
Early origins of obesity: programming the appetite regulatory system
J. Physiol., May 15, 2005; 565(1): 9 - 17.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
I. C. Mcmillen and J. S. Robinson
Developmental Origins of the Metabolic Syndrome: Prediction, Plasticity, and Programming
Physiol Rev, April 1, 2005; 85(2): 571 - 633.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
J. T Smith, P. J Mark, and B. J Waddell
Developmental increases in plasma leptin binding activity and tissue Ob-Re mRNA expression in the rat
J. Endocrinol., March 1, 2005; 184(3): 535 - 541.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
L. J. Edwards, J. R. McFarlane, K. G. Kauter, and I. C. McMillen
Impact of periconceptional nutrition on maternal and fetal leptin and fetal adiposity in singleton and twin pregnancies
Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2005; 288(1): R39 - R45.
[Abstract] [Full Text] [PDF]


Home page
J ANIM SCIHome page
T. G. Ramsay and M. P. Richards
Hormonal regulation of leptin and leptin receptor expression in porcine subcutaneous adipose tissue
J Anim Sci, December 1, 2004; 82(12): 3486 - 3492.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
L. C. Schulz and E. P. Widmaier
The Effect of Leptin on Mouse Trophoblast Cell Invasion
Biol Reprod, December 1, 2004; 71(6): 1963 - 1967.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
D. E. Edwards, R. P. Bohm Jr, J. Purcell, M. S. Ratterree, K. F. Swan, V. D. Castracane, and M. C. Henson
Two Isoforms of the Leptin Receptor Are Enhanced in Pregnancy-Specific Tissues and Soluble Leptin Receptor Is Enhanced in Maternal Serum with Advancing Gestation in the Baboon
Biol Reprod, November 1, 2004; 71(5): 1746 - 1752.
[Abstract] [Full Text] [PDF]


Home page
ReproductionHome page
A L Fowden and A J Forhead
Endocrine mechanisms of intrauterine programming
Reproduction, May 1, 2004; 127(5): 515 - 526.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
N. K. Ryan, K. H. Van der Hoek, S. A. Robertson, and R. J. Norman
Leptin and Leptin Receptor Expression in the Rat Ovary
Endocrinology, November 1, 2003; 144(11): 5006 - 5013.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
J. T. Smith and B. J. Waddell
Leptin Distribution and Metabolism in the Pregnant Rat: Transplacental Leptin Passage Increases in Late Gestation but Is Reduced by Excess Glucocorticoids
Endocrinology, July 1, 2003; 144(7): 3024 - 3030.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smith, J. T.
Right arrow Articles by Waddell, B. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, J. T.
Right arrow Articles by Waddell, B. J.
Agricola
Right arrow Articles by Smith, J. T.
Right arrow Articles by Waddell, B. J.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS